Metabiota, Inc.

Metabiota logo, current as of early 20222022-metabiota-logo.jpgSource : https://www.artemis.bm/news/metabiota-launches-epidemic-risk-modeling-platform-index/

Wikipedia 🌐 NONE

ASSOCIATIONS

2011 (June 20) - Video : "Nathan Wolfe - 2011 UW-Madison Big Learning Event"

Youtube channel uwacademictech (See livelink at https://www.youtube.com/watch?v=5-8CflEh6aA ) Saved 480p video : [HV00QE][GDrive]

Nathan Wolfe's presentation at the 2011 UW-Madison Big Learning Event. http://biglearningevent.wisc.edu/

2011 (Aug 31)

https://www.youtube.com/watch?v=pasWagdQSJ4

0:27 / 2:46

Global Viral Forecasting Founder Nathan Wolfe Interview⎢Virus Hunters⎢TakePart TV

3,397 viewsAug 31, 2011

Take Part

Subscribe for more TakePart TV now!: http://full.sc/SwIjS1

Global Viral Forecasting Founder Nathan Wolfe explains how his team is searching for humanity's next great plague... so we can stop it before it spreads.

TakePart TV is the channel from some of the people behind An Inconvenient Truth, Food Inc., The Help, Contagion and Waiting for Superman, among others. Here you'll find that entertainment doesn't always have to be mindless, and we hope you'll always find something real and eye-opening. Be sure to check out our shows, "like" and leave comments, and get involved as you see fit, because the only thing you can't do here is nothing.

2012 (Feb 19)

https://www.sfgate.com/health/article/Dr-Nathan-Wolfe-hunts-viruses-to-prevent-pandemic-3342262.php

2012 (Aug 30) - The Independent (London, UK) : "Hunting for the deadliest prey in the jungle; viruses"

Full newspaper pages : [HN020E][GDrive] / Clip above : [HN020F][GDrive]

2013 (Sep 07) - The Times-News (Twin Falls, Idaho) : ""New Study: Sizing up the viral threat"

Full newspaper page : [HN020G][GDrive] / Clip above : [HN020H][GDrive]

2014 (Sep 18) - Yes, they had a role with Ebola outbreak response .. .

Full newspaper page : [HN020I][GDrive] / Clip above : [HN020J][GDrive]

2015 (May 03) - NYTimes : "Review: ‘Frontline’ Looks at Missteps During the Ebola Outbreak"

https://www.nytimes.com/2015/05/04/arts/television/review-frontline-looks-at-missteps-during-the-ebola-outbreak.html?searchResultPosition=1

2015-05-04-nytimes-review-frontline-looks-at-missteps-during-the-ebola-outbreak.pdf

By Neil Genzlinger / May 3, 2015

Frontline An installment of this PBS program looks at the effects of Ebola on Liberia and other countries, as well as the origins of the outbreak.Heartbreaking stories from the Ebola outbreak are familiar by now, although that doesn’t make them any easier to hear, and a “Frontline” installment being broadcast on PBS on Tuesday night has its share. But it also has something less familiar: Officials acknowledging that they could have done a better job of responding to the crisis.

The program traces the outbreak to its origin, thought to be a tree full of bats in Guinea. And then it charts the early weeks, before the world took much notice, including the death of a revered traditional healer known as Mendinor along the border between Guinea and Sierra Leone. The customary funeral preparation, with its washing of the body, and the well-attended ceremony were the kinds of things that turned a small-scale problem into an out-of-control one.

“The healer’s funeral was a catastrophe,” the narration says. “It set off a chain reaction of infections that would ultimately lead to thousands of deaths.”

Customs and suspicions in the villages of Africa have taken a lot of blame, but the program also points fingers elsewhere as it explores why this outbreak became so severe even though other appearances of Ebola had been contained. The World Health Organization, it suggests, initially did not respond aggressively or with the right people. A company called Metabiota that was retained by Sierra Leone to assist with the response also comes across as overmatched.

The program says that the failure to follow chains of transmission early in the crisis cost lives. And at least one official candidly agrees.

“Contact tracing, I would say, is where we got it wrong,” says Dr. Amara Jambai, director of disease and prevention control for Sierra Leone’s health ministry. “We wasted like a month.”

More analysis of the Ebola outbreak lies ahead, of course, and much of it will no doubt come in the form of dry reports that certainly won’t be television-friendly. The “Frontline” examination does a nice job of at least beginning to ask the questions that need to be asked while keeping the human drama front and center.

  • Correction: May 5, 2015 : A television review on Monday about a “Frontline” report on PBS about the Ebola outbreak in West Africa last year misstated a word in a comment by Dr. Amara Jambai, the director of disease prevention and control for Sierra Leone’s healthy ministry. He said, “Contact tracing, I would say, is where we got it wrong,” not “contract tracing.”

2015 (August 27) - Video (Youtube) - "NASEM Health and Medicine Division"

https://www.youtube.com/watch?v=GejOX6zP-xo

8/27/2015 - Session 3: Wolfe

112 viewsSep 3, 2015

Nathan Wolfe, CEO, Metabiota

2016 (March 08) - The Honolulu Star Advertiser :

Full newspaper page : [HN020L][GDrive] / Clip above : [HN020M][GDrive]Same article : https://www.newspapers.com/image/522401900/?terms=metabiota&match=1 (Republican and Herald, Pottsville, PA)

text from AP News (see [HM0065][GDrive] ) : "AP Investigation: American company bungled Ebola response", by RAPHAEL SATTER

WASHINGTON – An American company that bills itself as a pioneer in tracking emerging epidemics made a series of costly mistakes during the 2014 Ebola outbreak that swept across West Africa – with employees feuding with fellow responders, contributing to misdiagnosed Ebola cases and repeatedly misreading the trajectory of the virus, an Associated Press investigation has found.

San Francisco-based Metabiota Inc. was tapped by the Sierra Leonean government and the World Health Organization to help monitor the spread of the virus and support the response after Ebola was discovered circulating in neighboring Guinea in March 2014. But emails obtained by AP and interviews with aid workers on the ground show that some of the company’s actions made an already chaotic situation worse.

WHO outbreak expert Dr. Eric Bertherat wrote to colleagues in a July 17, 2014, email about misdiagnoses and “total confusion” at the Sierra Leone government lab Metabiota shared with Tulane University in the city of Kenema. He said there was “no tracking of the samples” and “absolutely no control on what is being done.”

“This is a situation that WHO can no longer endorse,” he wrote.

Metabiota chief executive officer and founder Nathan Wolfe said there was no evidence his company was responsible for the lab blunders, that the reported squabbles were overblown and that any predictions made by his employees didn’t reflect the company’s position. He said Metabiota doesn’t specialize in outbreak response and that his employees stepped in to help and performed admirably amid the carnage of the world’s biggest-ever Ebola outbreak.

“Metabiota’s team worked tirelessly, skillfully and at substantial potential danger to themselves to assist when most of the world was still ignoring the problem,” he said in an email. “We are proud of our team efforts which went above and beyond the call of duty.”

Wolfe said some of the problems flagged were misunderstandings – and that others were planted by commercial rivals.

The complaints about Metabiota mirror the wider mismanagement that hamstrung the world’s response to Ebola, a disease that has killed upward of 11,000 people.

Previous AP reporting has shown that WHO resisted sounding the alarm over Ebola for two months on political, religious and economic grounds and failed to put together a decisive response even after the alert was issued. The turmoil that followed left health workers in Kenema bereft of protective equipment or even body bags and using expired chlorine, a crucial disinfectant.

WHO said Metabiota was well-placed to help when Ebola broke out in West Africa because of its expertise with Lassa, a related disease. The agency declined to give any detail about how it dealt with the complaints from senior staff about the firm or the status of their current relationship.

In Sierra Leone, Sylvia Blyden, who served as special executive assistant to the country’s president in the early days of the outbreak, said Metabiota’s response was a disaster.

“They messed up the entire region,” she said. She called Metabiota’s attempt to claim credit for its Ebola work “an insult for the memories of thousands of Africans who have died.”

‘The Viral Storm’

Wolfe, a swashbuckling scientist sometimes described as the Indiana Jones of virology, has focused his company’s work on disease hotspots such as West Africa in a bid to sniff out the next big threat. In his book, “The Viral Storm,” Wolfe writes that his work is aimed at hunting down “the first moments at the birth of a new pandemic” to prevent its global spread.

With a doctorate in immunology and infectious diseases from Harvard, Wolfe, 45, has found some serious backers. Metabiota and its nonprofit sister company Global Viral have received millions in funding from USAID, Google and the Skoll Foundation, among others. The Department of Defense alone has granted more than $18 million worth of contracts to the firm, federal records show.

In the early months of the outbreak, with WHO and the Centers for Disease Control and Prevention thin on the ground, Metabiota said it stepped in to help at the request of the Sierra Leonean government.

An account posted to its website says Metabiota provided “critical support” in the earliest days of the outbreak, organizing training, jointly running Sierra Leone’s Ebola laboratory, assisting with outbreak logistics and producing daily reports for the government.

Messages saved to ProMed, a mailing list for outbreak watchers, are upbeat, describing Metabiota’s tests and how it was teaching Sierra Leoneans how to set up Ebola isolation wards. On May 12, senior Metabiota scientist Dr. Jean-Paul Gonzalez said preparedness work had “ultimately protected, or at least uniquely prepared, Sierra Leone.”

But there were already reports of suspected infections in the country and, within weeks, the virus tore through Sierra Leone, overwhelming the hospital in Kenema where Metabiota shared the 700-square-foot lab with Tulane.

To some at Tulane, which had a long-established research project at the lab, Metabiota’s missteps were predictable. The two groups worked side-by-side in an uneasy relationship that observers said sometimes tipped into open conflict.

Tulane microbiology professor Bob Garry questioned whether Gonzalez was the right person to teach Sierra Leoneans how to protect themselves from Ebola. In 1994, the French researcher was at the center of a safety scare at Yale University after he accidentally infected himself with the rare Sabia virus and didn’t notify officials there for more than a week. The university put more than 100 people under surveillance and ordered Gonzalez to take a remedial safety course. Garry said that should have raised a red flag.

“Do you really want the person who infected himself with hemorrhagic fever going around explaining to people how to be safe?” he asked.

Gonzalez referred questions to a Metabiota press representative, who said in an email that the incident happened more than 20 years ago and that Gonzalez has extensive lab safety experience.

But Garry also faced questions; the WHO emails obtained by AP complaining about the Kenema lab are as critical of Tulane as they are of Metabiota.

Garry acknowledged mistakes but said they were understandable given the chaotic circumstances.

“We didn’t have the personnel and the infrastructure that was needed to handle the onslaught of cases that were coming,” he said. “We were doing the best we had with what we had there.”

‘They were at war’

As the death toll mounted in July, scientists from WHO, the United States and Canada were voicing concerns about what Metabiota and its Tulane colleagues were doing at the Kenema lab, according to the emails obtained by AP and interviews with those on the ground at the time.

When Gary Kobinger, head of special pathogens at the Public Health Agency of Canada, double-checked some of the facility’s work in mid-July, he found worrying discrepancies in four of eight tests and identified up to five people wrongly diagnosed with Ebola, among them a worker with the medical charity Doctors Without Borders.

Kobinger told AP in a telephone interview that the misdiagnoses he caught suggested many more had gone unnoticed.

“If you detect two, three, four, five, how many are out there?” he said.

The mistakes were doubly dangerous in a country where many mistrusted international workers, who were suspected of spreading Ebola deliberately, said Bertherat, the WHO outbreak expert. Attempts to reassure a jittery public could be “totally ruined if the population does not trust anymore in the diagnostic of the medical teams,” he wrote in an email.

Bertherat proposed two fixes for the problematic lab: WHO could either train Metabiota and Tulane staffers, or close down the facility and transfer all testing to another lab. He told his boss on July 18, 2014, that shutting down the shared lab was the “more prudent” option.

Five days later, Geneva-based WHO staffer Pat Drury emailed the agency’s chief, Dr. Margaret Chan, with criticism of both Tulane and Metabiota, referring to their shared facility as two labs.

“Both labs do not meet international standards for Biosecurity,” he said, adding that “several patients have been wrongly tested positive.”

Metabiota founder Wolfe said “we did wonderful lab work as far as I’m concerned.” Errors in the shared facility stopped once “other groups” were pulled from the testing and, in any case, he noted that Metabiota tested more than 1,800 samples. Even if any mistakes were made, he said the error rates were well within ranges seen elsewhere.

Wolfe did not name the “other groups,” but documents and interviews show Metabiota and Tulane blamed each other.

“On the surface, they were collaborating,” Kobinger said. But in reality, “they were at war.”

U.S. health official Austin Demby, who was sent to evaluate the lab’s work at the request of the CDC and Sierra Leone, said initial diagnostic tests carried out by Metabiota and Tulane clashed as often as 30 percent of the time. Errors raised the risk that the virus could be spread further by sending infected patients home or confining otherwise healthy people to infectious Ebola wards.

In a July 21 email to CDC and State Department officials, Demby put the blame at Tulane’s door, saying Metabiota’s tests were always closer to the mark and that Tulane’s “add no real value to the diagnosis.” But Tulane’s Garry said Metabiota’s staff stirred confusion by not following protocol.

Wolfe said that was “simply false.”

The lab’s set-up also was worrisome. Used needles littered the place, according to a worker who spoke on condition of anonymity because the worker was not authorized to speak to the media. Demby said in his email that the lab lacked an ultraviolet light for decontamination and didn’t have enough space to process blood samples safely.

“The cross contamination potential is huge and quite frankly unacceptable,” he wrote.

Tulane pulled the plug on its tests soon thereafter and the lab’s results improved. Kobinger credited Metabiota researcher Nadia Wauquier — “the hero of that whole gang” — with tightening procedures, but eventually the company was relieved of its testing duties and the CDC took over. Both Tulane and Metabiota say they stepped aside voluntarily.

‘They are sending wrong messages’

Outside the lab, the training touted by Metabiota unnerved some fellow responders.

Anja Wolz, an emergency coordinator with Doctors Without Borders, told AP in an interview that she saw Metabiota workers enter the homes of suspected Ebola patients without protective gear and without decontaminating themselves before leaving high-risk areas.

“They didn’t even have chlorine with them to wash their hands,” she said, adding that Metabiota project coordinator James Bangura told her they didn’t need the critical disinfectant.

“I didn’t go inside the Metabiota lab,” she said. “I refused to go because I had already seen enough.”

In a telephone interview, Bangura denied flouting safety measures.

Aid workers also complained that Metabiota employees including Bangura and a Ugandan consultant hijacked the outbreak response in Kenema, which was supposed to be directed by WHO.

Metabiota staffers “are systematically obstructing any attempt to improve the existing surveillance system and there are a lot of improvement(s) needed,” WHO Ebola coordinator Philippe Barboza said in an August 8, 2014, email. The next day, he argued that WHO should pull its outbreak staff from Kenema so they wouldn’t be tarred with Metabiota’s failures, writing he was “very concerned of the potential reputational risk for WHO.”

British disease expert Chris Lane echoed Barboza’s concerns. In a message to Barboza, he lamented that “much good work was achieved prior to the arrival of the Metabiota field staff.”

Barboza and Lane declined comment on the arguments. Metabiota officials acknowledged the dispute but downplayed it.

“It is inaccurate to suggest a major conflict between WHO and Metabiota,” Wolfe said, noting that Bangura was awarded a Sierra Leonean presidential silver medal for his Ebola efforts.

Nevertheless, the disagreement was serious enough that Metabiota said it fired the consultant and pulled Bangura from Kenema.

The consequences went beyond office politics. In one email, Barboza said 1 million euros in funding proposed by the International Rescue Committee was being held up because the donors wanted “a clear WHO leadership.”

Some responders said one of the most disturbing mistakes Metabiota employees made was misreading the epidemic.

Wolz, of Doctors Without Borders, said she recalled a meeting in the early summer as cases began multiplying “when I said that the outbreak was completely out of control.” She said Metabiota responded, ‘No, we know where we are, everything is OK.’”

Kobinger, the Canadian scientist, said Bangura would interpret temporary dips in the number of cases to mean that the outbreak was dissipating. He said he couldn’t fathom that reasoning given the number of Ebola-positive samples pouring into his own lab in nearby Kailahun.

Though Bangura said he did not personally make any estimates, Kobinger said Bangura told him in July that the outbreak would be over in “two or three weeks.”

Any suggestion Metabiota wrongly forecast the Ebola epidemic is rejected by Wolfe, who once wrote that his career is focused on creating systems “that can accurately detect pandemics early, determine their likely importance, and, with any luck, crush those that have the potential to devastate us.”

Wolfe told AP that his company couldn’t be held responsible for the predictions of employees seconded to Sierra Leone’s Health Ministry.

“We didn’t make forecasts. We loaned individuals to the ministry,” Wolfe said. “So the notion that somehow it’s a Metabiota forecast is simply completely inaccurate.”

Fellow responders may not have grasped the distinction. On Aug. 11 – just three days after WHO had declared the crisis a global emergency – Metabiota employees presented a slideshow to an Ebola task force. Next to a bar chart showing a slowdown in cases were the words: “The outbreak is stabilizing.”

WHO data specialist Mikiko Senga wasn’t persuaded.

“This is the kind of report we get from Metabiota epidemiologists,” she emailed colleagues from the presentation. “They are sending wrong messages. The outbreak is clearly not stabilizing.”

It was only in the second half of August that Kenema numbers began falling and, even then, the virus was merely moving to more populated areas.

Nearly two years after the virus was first discovered circulating near its border, Sierra Leone still is not officially Ebola-free.

‘They messed up on Ebola’

Despite doubts about Metabiota’s performance, Wolfe’s firm has largely been congratulated on its work in West Africa. In December 2014, it won a European Union grant to help validate new tests and treatments for the disease, something a company official said was in recognition of “the critical contributions our team has made in supporting the current outbreak.”

In 2015, the company raised some $30 million in investment from four U.S. investment firms intended to “support Metabiota’s efforts to further develop and deliver epidemic risk management worldwide,” according to a press release.

Even WHO has publicly credited Metabiota for its work during the outbreak. Months after Senga, one of its employees, complained privately about Metabiota’s optimistic predictions in Kenema, she wrote a sunnier account on WHO’s website.

“The fact that they were already there helped a lot,” she wrote in a post called “Ebola Diaries.” Tulane and Metabiota employees already being established in Kenema “made our case investigations and contact tracing work a lot easier,” she wrote.

Senga declined comment when reached by AP.

Guillaume Lachenal, a medical historian at Paris Diderot University who has followed Metabiota’s work in Africa, said it was indecent of the company to claim Ebola as a success story.

“They messed up on Ebola. That can happen,” he said. “To make a success story out of their Ebola response, that’s quite something.”

2016 (March 20) - The Baltimore Sun : "Firm bungled Ebola response"

Full page shown above : [HN020K][GDrive]

2016 (July 20) - Video from World Affairs Event : "FINDING THE NEXT PATIENT ZERO: THE GLOBAL VIROME PROJECT"

Live Link : https://www.youtube.com/watch?v=pQZgFxXgbsw / Saved video (720p) : [HV00QF][GDrive]

The frequency of epidemics is increasing, driven by surging populations, environmental change and globalized trade and travel. The SARS, pandemic influenza, MERS, Ebola and Zika virus outbreaks illustrate that the world is ill-prepared to deal with a large-scale viral pandemic. Experts have so far identified only a tiny proportion of viral threats, and few of these viruses have had vaccines or other counter-measures developed. Over the coming century we will witness spillover from a pool of over one million "unknown" viruses into human populations. The Global Virome Project is a global initiative to identify and characterize every significant viral threat circulating in the world. Only by identifying these potential threats can the world begin to prepare for the next great outbreak. In conversation with Jonna Mazet, Dennis Carroll and Nathan Wolfe, three experts from the Global Virome Project, this program will explore the extent of the viral threat to human populations and what can be done to stop it.

  • SPEAKERS

      • Dennis Carroll : Director, Global Health Security and Development Unit, US Agency for International Development (USAID)

      • Jonna Mazet : Executive Director, One Health Institute, UC Davis School of Veterinary Medicine

      • Nathan Wolfe : Founder and Chief Executive Officer, Metabiota

  • MODERATOR:

      • Larry Brilliant : Chair, Skoll Global Threats Fund

2016 (12)

https://www.statnews.com/2016/12/13/world-viruses-global-virome-project/

... and a comment by James Wilson ..

  • James Wilson

  • DECEMBER 13, 2016 AT 1:36 PM

  • The burning question STAT should have asked is whether any of these team members quoted in the piece provided critical intelligence that led to effective mitigation of ANY international public health crisis involving an infectious disease? The answer, to the best of my knowledge, is “no”. I would be happy to admit fault / wrong assumption here… but I ask anyone out there to show the evidence. If it is a fundamental science / research endeavor, then fine. But don’t imply operational relevance without proof of it.


Saved Wikipedia (March 21, 2022) - "Nita Madhav"

https://en.wikipedia.org/wiki/Nita_Madhav

2022-03-21-wikipedia-org-nita-madhav.pdf

https://drive.google.com/file/d/1V9i8mf172TmONf5yNg5kofv_Wn5OBMRm/view?usp=sharing

Nita Madhav is an epidemiologist and risk modeler who is currently CEO of Metabiota.[1]

Education

Madhav graduated from Yale University in 2002 with degrees in ecology and evolutionary biology, and received her Master's in Public health from Emory Universit yin 2005.[2]

Career

After time at the Centers for Disease Control and Prevention and AIR Worldwide,[3] Madhav joined Metabiota to work on infectious disease modeling and data science. During the ensuing five years, Madhav's team worked on models to predict epidemiological preparedness and readiness of economies to absorb losses experienced in these extreme, "Black swan theory" events.[4] These models were formalized into the Epidemic Preparedness Index.[5]

Along with colleagues from Stanford and Metabiota, Madhav co-authored a chapter on pandemic preparedness for the World Bank.[6]

She was promoted to CEO in 2019.[7]

In 2020, Madhav remarked that Metabiota's AI-powered models were capable of forecasting epidemics based on both formal and informal data sources.[8]

References


Confronting Emerging Zoonoses: The One Health Paradigm

Akio Yamada, Laura H. Kahn, Bruce Kaplan, Thomas P. Monath, Jack Woodall, Lisa Conti

Springer, Nov 19, 2014 - Medical - 254 pages

0 Reviews

This book provides readers with information on the factors underlying the emergence of infectious diseases originating in animals and spreading to people. The One Health concept recognizes the important links between human, animal, and environmental health and provides an important strategy in epidemic mitigation and prevention. The essential premise of the One Health concept is to break down the silos among the different health professions and promote transdisciplinary collaborations. These concepts are illustrated with in-depth analyses of specific zoonotic agents and with examples of the successes and challenges associated with implementing One Health. The book also highlights some of the challenges societies face in confronting several specific zoonotic diseases. A chapter is included on comparative medicine to demonstrate the broad scope of the One Health concept. Edited by a team including the One Health Initiative pro bono members, the book is dedicated to those studying zoonotic diseases and comparative medicine in both human and veterinary medicine, to those involved in the prevention and control of zoonotic infections and to those in the general public interested in the visionary field of One Health.

https://books.google.com/books?id=fbOLBQAAQBAJ&dq=%22monath%22+%2B+%22metabiota%22&source=gbs_navlinks_s

RESUME of NAME: James Wayne Le Due (aka: J.W. LeDuc)


https://usrtk.org/wp-content/uploads/2021/12/LeDuc-CV.pdf

2019-03-leduc-cv-redactions-usrtk-org.pdf

https://drive.google.com/file/d/1m_CkkCAMz_EH0KCq5fWmwuzKGdzYgtVW/view?usp=sharing

HHS0100201100015I/HHS010033002T, 09/01/2012-06/01/2013, 'Development of animal model for Burkholderia" (LeDuc PI, 2% effort; Tones Project Leader) $713,271, DHHS/BARDA

DTRA 01-03-D-0009, Subaward 798172-87M5 05/01/2013-09/30/2013. DoD/ Defense Threat Reduction Agency(LeDuc,subawardfromUniversityofNewMexico)$54,961. JointUniversityPartnership Collaboration with the Biological Threat Reduction Program. Development and implementation of a science program for the CPHR in Tbilisi, Georgia in the newly constructed laboratory.

HDTRA1-11-1-0032(Motin-PI,LeDuc-Co-I)06/15/11-06/14/14. DefenseThreatReductionAgency (DTRA),"Insights into HtunoraI Immunity to Plague" $138,399. The goal of this project is to unravel human immune responses to a live plague vaccine. (award terminated early due to State Department freeze on collaborations with Russia)

[ ... ]

Academic Engagement Partnership 10/01/2013-09/30/2017. DoD/ Defense Threat Reduction Agency (LeDuc, subaward PI from Metabiota) $1,790,000 (task order driven). Academic Engagement Partnership (AEP). Deliver custom-tailored, specialized training modules to develop scientific leaders.


Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. jpgonzalez@metabiota.com.

https://pubmed.ncbi.nlm.nih.gov/25421896/

Viruses

. 2014 Nov 24;6(11):4760-99. doi: 10.3390/v6114760.

Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014

Jens H Kuhn 1, Kristian G Andersen 2, Sylvain Baize 3, Yīmíng Bào 4, Sina Bavari 5, Nicolas Berthet 6, Olga Blinkova 7, J Rodney Brister 8, Anna N Clawson 9, Joseph Fair 10, Martin Gabriel 11, Robert F Garry 12, Stephen K Gire 13, Augustine Goba 14, Jean-Paul Gonzalez 15, Stephan Günther 16, Christian T Happi 17, Peter B Jahrling 18, Jimmy Kapetshi 19, Gary Kobinger 20, Jeffrey R Kugelman 21, Eric M Leroy 22, Gael Darren Maganga 23, Placide K Mbala 24, Lina M Moses 25, Jean-Jacques Muyembe-Tamfum 26, Magassouba N'Faly 27, Stuart T Nichol 28, Sunday A Omilabu 29, Gustavo Palacios 30, Daniel J Park 31, Janusz T Paweska 32, Sheli R Radoshitzky 33, Cynthia A Rossi 34, Pardis C Sabeti 35, John S Schieffelin 36, Randal J Schoepp 37, Rachel Sealfon 38, Robert Swanepoel 39, Jonathan S Towner 40, Jiro Wada 41, Nadia Wauquier 42, Nathan L Yozwiak 43, Pierre Formenty 44

Affiliations collapse

Affiliations

  • 1 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. kuhnjens@mail.nih.gov.

  • 2 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. kandersen@oeb.harvard.edu.

  • 3 Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France. sylvain.baize@inserm.fr.

  • 4 Information Engineering Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. bao@ncbi.nlm.nih.gov.

  • 5 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. sina.bavari.civ@mail.mil.

  • 6 Centre International de Recherches Médicales de Franceville, B. P. 769, Franceville, Gabon. nicolas.berthet@pasteur.fr.

  • 7 Information Engineering Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. olga.blinkova@nih.gov.

  • 8 Information Engineering Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. jamesbr@ncbi.nlm.nih.gov.

  • 9 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. anna@logosconsulting.us.

  • 10 Fondation Mérieux, Washington, DC 20036, USA. joseph.fair@fondation-merieux.org.

  • 11 Bernhard Nocht Institute for Tropical Medicine, World Health Organization (WHO) Collaborating Center for Arbovirus and Hemorrhagic Fever Reference and Research, and the German Center for Infection Research (DZIF), Partner Site Hamburg, 20259 Hamburg, Germany. gabriel@bni-hamburg.de.

  • 12 Tulane University School of Medicine, New Orleans, LA 70112, USA. rfgarry@tulane.edu.

  • 13 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. sgire@oeb.harvard.edu.

  • 14 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. augstgoba@yahoo.com.

  • 15 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. jpgonzalez@metabiota.com.

  • 16 Bernhard Nocht Institute for Tropical Medicine, World Health Organization (WHO) Collaborating Center for Arbovirus and Hemorrhagic Fever Reference and Research, and the German Center for Infection Research (DZIF), Partner Site Hamburg, 20259 Hamburg, Germany. guenther@bni.uni-hamburg.de.

  • 17 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. happic@run.edu.ng.

  • 18 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. jahrlingp@niaid.nih.gov.

  • 19 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. jimmy_kap@hotmail.com.

  • 20 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. gary.kobinger@phac-aspc.gc.ca.

  • 21 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. jeffrey.r.kugelman.mil@mail.mil.

  • 22 Centre International de Recherches Médicales de Franceville, B. P. 769, Franceville, Gabon. eric.leroy@ird.fr.

  • 23 Centre International de Recherches Médicales de Franceville, B. P. 769, Franceville, Gabon. gael_maganga@yahoo.fr.

  • 24 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. mbalaplacide@gmail.com.

  • 25 Tulane University School of Medicine, New Orleans, LA 70112, USA. lmoses2@tulane.edu.

  • 26 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. muyembejj@gmail.com.

  • 27 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. cmagassouba01@gmail.com.

  • 28 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. stn1@cdc.gov.

  • 29 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. omilabusa@yahoo.com.

  • 30 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. gustavo.f.palacios.ctr@us.army.mil.

  • 31 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. dpark@broadinstitute.org.

  • 32 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. januszp@nicd.ac.za.

  • 33 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. sheli.r.radoshitzky.ctr@mail.mil.

  • 34 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. cynthia.a.rossi.civ@mail.mil.

  • 35 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. pardis@broadinstitute.org.

  • 36 Tulane University School of Medicine, New Orleans, LA 70112, USA. jschieff@tulane.edu.

  • 37 United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA. randal.j.schoepp.civ@mail.mil.

  • 38 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. sealfon@gmail.com.

  • 39 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. bobswanepoel@gmail.com.

  • 40 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. jit8@cdc.gov.

  • 41 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. wadaj@niaid.nih.gov.

  • 42 Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD 21702, USA. nadia.wauquier@gmail.com.

  • 43 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. nyozwiak@broadinstitute.org.

  • 44 FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA. formentyp@who.int.

Free PMC article

Abstract

In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa. Epidemiological and evolutionary analyses confirmed that all cases of both outbreaks are connected to a single introduction each of EBOV into human populations and that both outbreaks are not directly connected. Coding-complete genomic sequence analyses of isolates revealed that the two outbreaks were caused by two novel EBOV variants, and initial clinical observations suggest that neither of them should be considered strains. Here we present consensus decisions on naming for both variants (West Africa: "Makona", Middle Africa: "Lomela") and provide database-compatible full, shortened, and abbreviated names that are in line with recently established filovirus sub-species nomenclatures.

https://www.researchgate.net/profile/Jean-Paul-Gonzalez

https://apnews.com/article/4c2f9c4ed09db53cdb7e8fac443dca76

https://www.npr.org/sections/goatsandsoda/2014/09/12/346114454/how-do-you-catch-ebola-by-air-sweat-or-water

https://mk-mk.facebook.com/CEEZAD/videos/dr-richt-attends-international-scientific-and-practical-confe/1575642105802392/

Center of Excellence for Emerging and Zoonotic Animal Diseases

22 јуни 2017

·

Следи

Dr. Richt attends International Scientific and Practical Conference on Transboundary Emergent Animal...

Види повеќе



1994, Sabia, Level 3:

In August of 1994, Sabia was a little known virus, having only been discovered the year before on a Navajo reservation in New Mexico. Like the other members of its family, it can cause headaches, muscle aches, vomiting, and internal bleeding. In late 1994, Dr. Jean-Paul Gonzalez was working with the virus in a test tube, wearing just a lab coat, a facemask, and gloves in a biosafety level 3 lab at Yale University. Then the test tube broke while spinning in a centrifuge, hurling its contents into the air. Following procedure, Gonzalez decontaminated the spill and hopped into a shower, dousing himself with a bleach-like solution. But he was alone in the lab at the time and did not report the incident. Even when he developed a fever a week later, he waited four more days before entering a hospital. By that time, he had exposed colleagues, friends, and family. He would go on to expose 139 people before being released.

https://nautil.us/infected-monkeys-and-other-cautionary-tales-from-the-biolab-3326/


Saved Wikipedia (March 21, 2022) - "Jean-Paul Gonzalez"

https://en.wikipedia.org/wiki/Jean-Paul_Gonzalez

2022-03-21-wikipedia-org-jean-paul-gonzalez.pdf

https://drive.google.com/file/d/1eoC7bLmHgRqp2LQGPms6WoCSnNidmmp_/view?usp=sharing

Jean-Paul Joseph Gonzalez (born August 28, 1947) is a French virologist. He graduated from the Medical School of Bordeaux University(M.D., Internal Medicine) France.

Jean Paul Gonzalez conducting public health interview in Laos

Research career

Gonzalez is a virologist[1] whose main fields of research encompass the fundamentals and domains of disease emergence,[2] viral disease and eco-epidemiology (i.e. arbovirology, viral hemorrhagic fevers).[3][4][5][6] He received his PhD in viral ecology in 1984 from the University of Clermont-Ferrand[7] in France. He was recruited by the French Institute of Research for Development, IRD (alias ORSTOM), and he dedicated his career to research, training, and providing expertise for developing countries across the Americas, Africa and Asia. He has led field and laboratory teams of researchers in countries such as Brazil, Central African Republic, Gabon,[8] Laos, Senegal, Sierra-Leone, Thailand, Ukraine and more. He worked as a fellow at the Center for Disease Control and Prevention in Atlanta and Fort Collins, and as a visiting professor at the Yale Arbovirus Research Unit[9](Yale University, School of Medicine). Gonzalez has been involved in high security laboratory practices and research and, early development of geographical information systems applied to infectious diseases. He and his teams have identified new pathogens for humans and animals, have developed tools and strategies for bio-surveillance, and control and prevention of highly infectious transmitted disease (i.e.: high consequence pathogens[10]). He has developed several scientific concepts and research strategies for health (e.g.: long lasting co-evolution of germs and hosts). He was instrumental to introduce and applied the concept of One Health in low income countries.

Early life

Gonzalez was born and raised near the town of Saint Georges de Didonne in South-West of France in 1947. His father, Jesus Gonzalez, was a Spanish immigrant, born in Madrid who fled from General Franco’s regime to France during the Spanish Civil War. Jean-Paul's mother, Jeanne Charlotte Rives, was third daughter of a barrel maker from the Blaye vineyard of Bordeaux. She raised their three children (Denis, Denise and Jean-Paul).

Medical learning and research

Gonzalez graduated from the Medical School of Bordeaux University in 1974. By attending the same school, he also got a Master on Tropical Medicine and Hygiene as well as a Medical Diploma of the French Commercial Navy.

This was followed by a residence in French Guiana at the Hôpital André-Bouron, located on the left bank of the Maroni River on the amazonian forest. Gonzalez was in charge of the adult, pediatric, and geriatric wards, as well of the Acarouany leprosy hospital and, health control over the Maroni River border between French Guiana and Suriname. He returned to Bordeaux and took the position of associate professor of Parasitology and Fundamental Sciences at Bordeaux School of Medicine and as medical attendant at the Children Teaching Hopital (Hôpital des Enfants Malades[11]). He also worked at the Saint-André Teaching Hospital as a biologist.

Gonzalez did its 18 months national duty as a Volunteer at the National Active Service (VSNA) at the Pasteur Institute of Tunis (Tunisia) where he traveled extensively for the Pasteur Institute as a WHO (World Health Organization) expert collecting mosquitoes’ larvae and identifying imago for the surveillance of malaria in Tunisia. There he published several fundamental articles on the Tunisian endemic fauna parasites (fresh water turtles,[12][13] rodents[13] and cockroaches). Gonzalez later spent more than ten years as laboratory chief, and then department head within the Institut Pasteur International Network[14] (RIIP) in Bangui, Central African Republic, and in Dakar.

Jean Paul Gonzalez and team training public health workers for viral hemorrhagic fever preparedness and response

In 1990 he was one of the first foreign doctors to work at the high containment laboratory (BSL4) in Atlanta. There he analyzed all the samples previously collected in Central Africa in search of Viral Hemorrhagic Fever traces including Ebola and Marburg,[15][16] Arenavirus,[17] Hantavirus,[18][19]Crimean Congo Hemorrhagic[20] virus and others. In the late 90s he began working as a professor of Epidemiology and Public Health at the Yale School of Medicine; focusing on arboviruses and hemorrhagic viral fevers including Argentinian, Bolivian, Brazilian,[21] Venezuelan,[22][23] and Dengue fevers[24][25] among others.

Since the early 1980s to date he continues to study, train and give expertise on Viral Hemorrhagic fevers including, among others, a follow up on Ebola fever (alias Ebolavirus Disease)[26][27][28][29][30][31][32] and other high consequence pathogens.[33][34]

From 2008 to 2012 he was appointed as General Director of the International Center of Medical Research of Franceville, Republic of Gabon (CIRMF). Appointed there by the French Ministry of Europe and Foreign Affairs and, then nominated at the direction position by the Gabon President (H.E. Omar Bongo), he intensively participate to the development of innovative field of research of interest for Gabon’ public health, including preparedness and response of high consequent pathogens,[35][36] One Health approach as a tool for public health improvement,[37] co-founded the Central African Network for Sickle Cell Study (REDAC), among other advancements.

In 2012, he joined Metabiota,[38] Inc. as Senior Staff Scientist, where he uses his expertise on emerging viral disease,[39] biosafety, biosecurity and bio-surveillance, and trains scientists from low income countries of Africa[40] and Eastern Europe.[41] In 2017 he was appointed at Deputy Director of the Center of Excellence for Animal and Zoonotic Diseases (CEEZAD[42]), Kansas State University (KSU).[43][44] Where his work focuses extensively on zoonosis,[45][46] perpetuating also his engagement on One Health approach (One Health News Letter) and Global Health.

He has published more than 250 peers reviewed (NCBI[47]) scientific papers, books[48] and book chapters.

Jean Paul Gonzalez presenting the Center of Excellence of Emerging Zoonotic and Animal Disease (Kansas State University, Manhattan, KS) at University of Kansas School of Medicine, Lawrence, KS.

References



RESUMEhttps://independent.academia.edu/JeanpaulGonzalez/CurriculumVitae2015-est-cv-jean-paul-gonzalez.docxhttps://docs.google.com/document/d/1069yF1Hch3DbEnoppyxvNfyORBsaubO9/edit?usp=sharing&ouid=113596148250768822587&rtpof=true&sd=true

https://gufaculty360.georgetown.edu/s/contact/0031Q000027PbL3QAK/jean-paul-gonzalez

2022-03-21-georgetown-edu-website-jean-paul-gonzalez.pdf

2022-03-21-georgetown-edu-website-jean-paul-gonzalez-img-1

Jean Paul J Gonzalez

GUMC Adjunct -- Professor | Main Campus Non-Ordinary -- Adjunct

M.D. (Internal Medicine, Global Health, One Health); Ph.D. (Molecular Virology and Genetics)

Contact

Email: jjg128@georgetown.edu

Social Media

LinkedIn Link

Personal Website(s)

Wiki

Research Gate

One Health NewsLetter (Editor)

Bio and Featured Works

Jean-Paul Joseph Gonzalez graduated as MD (Internal Medicine) from the Medical School of Bordeaux University, France. He did his French National Duty at the Pasteur Institute of Tunis, Tunisia (National Biosurveillance), and earned a Ph.D. in Virology (Molecular Biology and Genetics) from the Faculty of Sciences of Clermont-Auvergne University, France.

After his internship at the remote Teaching Hospital of Saint Laurent du Maroni in French Amazonian Guiana, he spends a carrier as a medical practitioner and researcher out of the French Metropolitan territory. Thus, he works for the Pasteur Institute International Network and the French Institute of Research for Development implementing research, training and expertise for developing countries across Americas, Africa and Asia.

As a research director of both organisations, he has led field and laboratory teams of researchers from several partner institutions of different countries, including Brazil, Cameroon, Central African Republic, Gabon, Senegal, Thailand, Laos, among others. He earned a fellowship (Viral Haemorrhagic Fevers) of the Centres for Disease Control and Prevention (Atlanta; Fort Collins), and, was invited as a visiting professor of Epidemiology and Public Health at the Medical School of Yale University (Yale Arbovirus Research Unit).

His main fields of research and expertise encompass the understanding fundamentals and domains of disease emergence, viral disease eco-epidemiology, biosafety, biosecurity and biosurveillance. Mainly, he and his teams identified new human and animal pathogens, developed tools and strategies for biosurveillance, control and prevention of highly pathogenic infectious disease, revisited the spread and dynamics of viral haemorrhagic fevers in Africa and Asia. Also, as an operative in the field of epidemic response and control, he worked with his partners to train national health workers (e.g.: Nigeria, Uganda), developed vaccine clinical trials (e.g. Rift Valley haemorrhagic fever in Senegal; Dengue in Thailand) and, respond to outbreaks (e.g. Ebola Virus Disease in Sierra Leone).

He developed several scientific concepts (e.g.: long term co-evolution of germs and hosts) and, research strategies for public health (e.g.: Telemedicine and limited access to health; The central role of subclinical infection of endemic pathogens). As Global Health expert, he belongs to several institutional advising board worldwide.

From 2017 to 2109, Doctor Gonzalez was appointed at Kansas State University as a Deputy Director of the Centre of Excellence for Emerging Zoonosis and Animal Diseases, perpetuating is engagement on One Health approach where he worked extensively on zoonotic diseases and food security.

On August 2019 he has been appointed at Adjunct professor at the Department of Microbiology & Immunology, Division of Biomedical Graduate Research Organization, School of Medicine, Georgetown University.

Dr. Gonzalez continues to teach and mentor students and scientists at Georgetown University on public health policy with a focus on the importance of systems (biotic and abiotic, social and economic) and multiple and changing environments.

He published more than 300 peer reviewed scientific manuscripts, book chapters and books (accessible through the National Center for Biotechnology Information (NCBI/PubMed).

Expertise

Global Health, Human Rights In Emerging Infectious Disease Outbreaks, Infectious Diseases, International Health Regulations, Microbiology, Molecular Biology, One Health, Pandemic Preparedness, Pandemic Preparedness, Vaccinology, Virus Therapy, Zoonotic Diseases

Interests

Zoonotic Diseases, Pathogen and Data Sharing, Coronavirus, Infectious Diseases, Microbiology, Pandemic Preparedness, Pathogen and Disease Evolution, Tropical Medicine, Virus Therapy, Zoonotic Diseases

Language(s)

English (Speak Read Write)

French (Speak Read Write)

Spanish (Speak Read Write)



2021 (June 15) iCrowdNewswire : Metabiota Awarded as Technology Pioneer by World Economic Forum

https://icrowdnewswire.com/2021/06/15/metabiota-awarded-as-technology-pioneer-by-world-economic-forum/

2021-06-15-icrowdnewswire-com-metabiota-awarded-as-technology-pioneer-by-world-economic-forum.pdf

2021-06-15-icrowdnewswire-com-metabiota-awarded-as-technology-pioneer-by-world-economic-forum-img-1.jpg

San Francisco, California, 15 June 2021 – Metabiota, the San Francisco-based company that specializes in infectious disease risk analytics, was selected among hundreds of candidates as one of the World Economic Forum’s “Technology Pioneers”. Founded in 2008, Metabiota has over a decade of experience partnering with businesses and governments worldwide to build resilience to epidemics and protect global public health.

The World Economic Forum’s Technology Pioneers are early to growth-stage companies from around the world that are involved in the use of new technologies and innovation that are poised to have a significant impact on business and society.

With their selection as Technology Pioneer, CEO Nita Madhav of Metabiota will be invited to participate at World Economic Forum activities, events, and discussions throughout the year. Metabiota will also contribute to Forum initiatives over the next two years, working with global leaders to help address key industry and societal issues.

“We’re excited to welcome Metabiota to our 2021 cohort of Technology Pioneers,” says Susan Nesbitt, Head of the Global Innovators Community, World Economic Forum. “Metabiota and its fellow pioneers are developing technologies that can help society solve some of its most pressing issues. We look forward to their contribution to the World Economic Forum in its commitment to improving the state of the world.”

“It’s a great honor to be acknowledged as a pioneer by the World Economic Forum”, said Metabiota’s Nita Madhav. “This provides validation that our technology is among the most unique in the world to build health systems, societies, and economies that are more resilient to infectious diseases. Our technology can help risk mitigation efforts as infectious diseases continue to pose an increasing global threat. We look forward to contributing to the Forum dialogues on this challenge.”

For the first time in the community’s history, over 30% of the cohort are led by women. The firms also come from regions all around the world, extending their community far beyond Silicon Valley. This year’s cohort includes start-ups from 26 countries, with UAE, El Salvador, Ethiopia and Zimbabwe represented for the first time.

The diversity of these companies extends to their innovations as well. 2021 Tech Pioneer firms are shaping the future by advancing technologies such as AI, IoT, robotics, blockchain, biotechnology, and many more. The full list of Technology Pioneers can be found here.

Technology Pioneers have been selected based on the community’s selection criteria, which includes innovation, impact, and leadership as well as the company’s relevance with the World Economic Forum’s Platforms.

All info on this year’s Technology Pioneers can be found here: http://wef.ch/techpioneers21 .

  • About Metabiota: Metabiota has been on the leading edge of helping organizations navigate infectious disease threats for over a decade. Metabiota works with governments and industry to proactively estimate, anticipate, mitigate and manage epidemic risk, supporting global health security, sustainable development, and data-driven decisions. The team includes global leaders in epidemiology, veterinary medicine, laboratory science, data science, actuarial science, social science, and political economics. The company’s international footprint includes offices in San Francisco, Cameroon, and the Democratic Republic of the Congo. (www.metabiota.com).
  • About World Economic Forum: The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, and other leaders of society to shape global, regional, and industry agendas. (www.weforum.org). The World Economic Forum believes that innovation is critical to the future well-being of society and to driving economic growth. Launched in 2000, the Technology Pioneer community is composed of early to growth-stage companies from around the world that are involved in the design, development, and deployment of new technologies and innovations, and are poised to have a significant impact on business and society. The World Economic Forum provides the Technology Pioneers community with a platform to engage with the public- and private-sector leaders and to contribute new solutions to overcome the current crisis and build future resiliency.

https://www.survivethenews.com/exclusive-ceo-of-metabiota-nathan-wolfe-connected-to-hunter-biden-the-nih-the-cdc-and-the-world-economic-forum/

EXCLUSIVE: CEO of Metabiota, Nathan Wolfe, Connected to Hunter Biden, the NIH, the CDC and the World Economic Forum

Nathan Wolfe, the CEO of Metabiota, has connections to the NIH, Biolabs in Ukraine and Hunter Biden. Is this why the Biden gang is trying to hide the Biolabs in Ukraine?

This past week all over the news was the fact that the US had Biolabs in Ukraine. This fact was reported on by Russia and discussed in the Senate and UN as well. There appears to be no question that these labs in Ukraine were built or updated by the US.

We know that Hunter’s firm, Rosemont Seneca, invested in Metabiota and provided evidence of this from the Wayback Machine. We also know that Metabiota received contracts from Black & Veatch (B&V) which was involved in contracts in Ukraine to build facilities that were working with pathogens (Biolabs).

TRENDING: George Soros: United States, European Union Must Remove Putin And Xi From Power ‘Before They Can Destroy Our Civilization’

The CEO of Metabiota has a unique history. Per his LinkedIn profile, Nathan Wolfe, created Metabiota in 2008. He also indicates that he “has been honored with a Fulbright fellowship, the NIH Director’s Pioneer Award, [and] a World Economic Forum Young Global Leader.”

Below is the corporate filing for Metabiota which was filed in California:

Metabiota CA Corporate Filing by Jim Hoft on Scribd

In Metabiota web pages found in the Way Back Machine, Metabiota has partners around the world, but especially in the US. Look at some of its partners. Notice Black and Veatch, Centers for Disease Control and Prevention (CDC), the DOD, the State Department, and USAID in particular.

https://www.reddit.com/gallery/s359mx

37

Posted byu/parkstar86

2 months ago

Meet Dr. Nathan Wolfe in a nutshell. From Epstein/Maxwell to Elite University to Clown funded „Metabiota“ to DARPA/NIH/USAID $ to foreign countries - and somehow again EcoHealth and the WiV appear again

reddit-ibbqmrw9uhb81.jpg

reddit-2m8kzvw9uhb81

reddit-lmtw3sw9uhb81

https://www.globalviromeproject.org/who-we-are/leadership/dennis-carroll

2022-03-23-globalvironeproject-org-who-we-are-leadership-dennis-carroll-img-1

DENNIS CARROLL serves as the Chair of the Global Virome Project Leadership Board. Dennis previously served as the Director of the U.S. Agency for International Development's (USAID's) Pandemic Influenza and other Emerging Threats Unit. In this position, he led USAID's Emerging Pandemic Threats program - a global effort to combat new disease threats before they can become significant threats to human health. Dennis was responsible for providing strategic and operational leadership for the agency's programs addressing new and emerging disease threats, which included leading the agency's response to the H5N1 avian influenza and H1N1 pandemic viral threats.

Dennis was initially detailed to USAID from the U.S. Centers for Disease Control and Prevention as a senior public health advisor in 1991. In 1995 he was named the agency's Senior Infectious Diseases advisor, responsible for overseeing the agency's programs in malaria, tuberculosis, antimicrobial resistance, disease surveillance, as well as neglected and emerging infectious diseases. In this capacity Dennis was directly involved in the development and introduction of a range of new technologies for disease prevention and control, including community-based delivery of treatment of onchocerciasis, rapid diagnostics for malaria, new treatment therapies for drug-resistant malaria, intermittent therapy for pregnant women and “long-lasting” insecticide-treated bed nets for prevention of malaria. He was responsible for the initial design and development of the President's Malaria Initiative. Dennis officially left the CDC and joined USAID in 2005 when he assumed responsibility for leading the USAID response to the spread of avian influenza.

Dennis has a doctorate in biomedical research with a special focus in tropical infectious diseases from the University of Massachusetts Amherst. He was a Research Scientist at Cold Spring Harbor Laboratory where he studied the molecular mechanics of viral infection. Dennis has received awards from both the CDC and USAID, including the 2006 USAID Science and Technology Award for his work on malaria and avian influenza, and the 2008 Administrator's Management Innovation Award for his management of the Agency's Avian and Pandemic Influenza program.